financetom
Business
financetom
/
Business
/
L3 Harris Among Defense Stocks Rising After Hegseth Reportedly Calls Military Meeting
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
L3 Harris Among Defense Stocks Rising After Hegseth Reportedly Calls Military Meeting
Sep 25, 2025 9:50 AM

12:24 PM EDT, 09/25/2025 (MT Newswires) -- L3 Harris Technologies (LHX), Northrop Grumman ( NOC ) and other defense stocks were rising in recent Thursday trading after Defense Secretary Pete Hegseth reportedly ordered hundreds of US military generals and admirals to gather next week at a Marine Corps base in Virginia.

The order was issued earlier this week to virtually all top military commanders around the world, The Washington Post reported Thursday, citing more than a dozen people familiar with the matter.

No reason was given for the meeting scheduled for Tuesday in Quantico, causing confusion and concern, according to the report.

In a brief statement, Pentagon spokesman Sean Parnell confirmed that Hegseth will address senior military leaders next week but did not share any further details.

L3Harris Technologies ( LHX ) shares were up 1.8%, Boeing ( BA ) advanced marginally, and Northrop Grumman ( NOC ) and Lockheed Martin ( LMT ) added 0.1% in recent trading activity Thursday.

Price: 215.19, Change: +0.09, Percent Change: +0.04

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Tyra Biosciences' TYRA-300 Gets US FDA Clearance for Phase 2 Trial in Non-Muscle Invasive Bladder Cancer
Tyra Biosciences' TYRA-300 Gets US FDA Clearance for Phase 2 Trial in Non-Muscle Invasive Bladder Cancer
Jan 10, 2025
10:49 AM EST, 01/10/2025 (MT Newswires) -- Tyra Biosciences ( TYRA ) said Friday it obtained investigational new drug clearance from the US Food and Drug Administration for TYRA-300, moving to a phase 2 trial of the potential drug for non-muscle invasive bladder cancer. The phase 2 SURF302 trial targets to enroll up to 90 participants at several sites mainly...
ModivCare Raises $105 Million in Financing; Shares Fall
ModivCare Raises $105 Million in Financing; Shares Fall
Jan 10, 2025
10:54 AM EST, 01/10/2025 (MT Newswires) -- ModivCare ( MODV ) said Friday it has secured $105 million in additional financing from stakeholders across its capital structure to provide liquidity for its strategic initiatives. The financing comes from a $75 million incremental term loan under its credit agreement and, subject to a stockholder vote, $30 million of new Second Lien...
Factbox-New U.S. sanctions against Russian energy interests
Factbox-New U.S. sanctions against Russian energy interests
Jan 10, 2025
(Reuters) - The U.S. Treasury on Friday announced sweeping new sanctions against the Russian energy sector, including oil majors Gazprom Neft and Surgutneftegaz, to try to hinder Moscow in its war with Ukraine. Britain also joined the sanctions against those two companies, the U.S. Treasury said. The sanctions also target more than 180 vessels and dozens of oil traders, oilfield...
Dyne Therapeutics' Muscle Dystrophy Treatment Demonstrates DMPK Reduction, Splicing Correction; Shares Fall
Dyne Therapeutics' Muscle Dystrophy Treatment Demonstrates DMPK Reduction, Splicing Correction; Shares Fall
Jan 10, 2025
10:49 AM EST, 01/10/2025 (MT Newswires) -- Dyne Therapeutics ( DYN ) said Friday that new clinical data from its ongoing phase 1/2 trial of DYNE-101 in people with myotonic dystrophy type 1 demonstrated a compelling impact on key disease biomarkers. This included the knockdown of dystrophin myotonic protein kinase, or DMPK, and splicing correction at the 6.8 mg/kg Q8W...
Copyright 2023-2026 - www.financetom.com All Rights Reserved